human BM followed by cytokine injections allows a substantial prolongation of survival of human myeloid progenitors. ' The severe combined immunodeficient (SCID)-human (hu) thymusAiver (Thykiv) grafts produce phenotypically normal human T-cells into the periphery for prolonged periods, allowing mechanisms of tolerance induction and T-cell repertoire to be ~t u d i e d .~"~ In addition, SCID-hu mice have been valuable tools for the study of human hematopoietic stem cell devel~pment'~.'~ and human immunodeficiency virus
However the potential for a number of applications is limited by the large number of human cells required for engraftment, possibly because of the presence of reactive natural killer (NK) cells2'.22 or because of clearance by cells in the mononuclear phagocytic system. Each of these experimental techniques would be greatly improved by providing a means to allow human cells to survive and circulate freely in the periphery of immunocompromised mice.
The spleen and other tissues of the mononuclear phagocyte system are important sites of phagocytosis of both opsonized and nonopsonized particles as well as in the early phase of bacterial in~asion.'~ Macrophages do not ingest small molecules, but do ingest lipo~omes,'~ and, therefore, can be targeted using liposomes as vehicles for foreign molecules. Specific elimination of phagocytic cells in the spleen and liver can be acheived within 24 hours after a single intravenous injection of liposome-encapsulated C12MDP.25.26 However, injection of free C12MDP or phosphate-buffered saline (PBS)-encapsulated liposomes does not result in macrophage depletion. A single intravenous injection of C1,MDP-containing liposomes results in disappearance of splenic red pulp and marginal zone macrophages, with recovery of these subpopulations occumng after l to 2 weeks and greater than 1 month, re~pectively.'~ The macrophage depletion can be sustained for prolonged periods (at least 1 month) with sequential intravenous injections?' Nonphago- cytic spleen cells including neutrophils remain morphologically normal and retain normal functional capacities such as protein production, and antigen-specific T-cell proliferat i~n . *~-~' These characteristics of C12MDP-liposome-mediated macrophage depletion make it an attractive system in which to study the function of murine phagocytic cells in the clearance of human cells in SCID-hu models.
In this study, we have shown the ability of C12MDP liposomes to effectively eliminate murine macrophages in the red pulp of the spleen of SCID mice, and allow prolonged circulation of intravenously injected human PB cells. In addition, injection of ClzMDP-containing liposomes into SCIDhu mice resulted in a transient increase of human cells in the PB, and an accumulation of human T-cells in the splenic white pulp.
MATERIALS AND METHODS
SCID-hu mice. Fetal tissues were obtained, and thymus and liver tissues transplanted into SCID mice as previously described? Breifly, fetal tissues were obtained from 18-to 23-week-old elective abortuses, and small (2-mm) Thy and Liv fragments placed adjacent under the kidney capsule of 6-to 8-week-old anesthetized C.B-17 scidscid mice.
Liposome preparation. C1,MDP-liposomes were prepared as described p r e v i o~s l y .~~ In brief, 75 mg phosphatidyl choline (a gift of LIPOID KG, Ludwigshafen, Germany) and 11 mg cholesterol (Sigma, St Louis, MO) were dissolved in chloroform in a round bottom flask. After low vacuum rotary evaporation at 37°C the lipids were dispersed by gentle rotation in 10 m1 PBS in which 2.5 g dichloromethylene diphosphonate (a gift of Boehringer Mannheim, Mannheim, Germany) was dissolved. The resulting liposomes were washed twice at 100,OOOg for 30 minutes to remove free, nonen- trapped dichloromethylene diphosphonate. The liposomes were then resuspended in 4-mL (100% stock).
Human PB samples. PB was obtained from healthy donors and 1 to 2 X 10' cells overlayed on 15 mL Ficoll (Pharmacia, Uppsala, Sweden) and spun for 25 minutes. Interface cells were collected, washed twice in fluorescence-activated cell sorting (FACS) media (PBS, 0.2% bovine serum albumin) and resuspended in FACS media for injection into SCID mice.
Anribodies. Mouse antibodies against human leukocyte markers were directly conjugated with phycoerythrin (PE), fluorescein isothiocyanate (FITC) or tri-color (TC). These included antibodies against human CD4, CD8, CD20 (Becton Dickinson, Mountainview, CA), and CD45 (Caltag, South San Francisco, CA). FITC-conjugated monoclonal antibody (MoAb) pan-human HLA class I marker W6/ 32 was derived from hybridoma obtained from American Type Culture Collection (Rockville, MD) and fluorochrome conjugated at SyStemix (Palo Alto, CA). Irrelevant isotype controls were directly FITC-conjugated IgGl (Becton Dickinson) and TC-conjugated IgG2A (Caltag). Mouse pan-leukocyte marker MoAb Ly5.1 was biotinylated and visualized with second stage PE-conjugated streptavidin (Becton Dickinson). Rat antibodies against mouse myeloid cells included C D l l b (Mac-la) or myeloid differentiation antigen (Gr-l) (Pharmingen, San Diego, CA), which were visualized with a secondary PE-conjugated mouse anti-rat IgG (Southern Biotech, Birmingham, AL).
Analysis of human cells circulating in SCID mice. Mouse PB was collected by tail vein into PBS containing 8 mglmL EDTA. Spleens and BM were removed from dead animals and in some cases, one half of the spleen was taken for immunohistology. Spleen and BM cells were manipulated into single cell suspensions. All samples were RBC lysed with ammonium chloride, washed, and blocked with 1 mg/mL human gamma-globulin (Gamimune, Miles Inc, Elkhart, IN). Total viable cell content was determined by trypan blue exclusion, and cells were incubated in FACS buffer for 20 minutes on ice with directly conjugated antibodies. In the case where cells were stained with Ly5.1-biotin, cells were washed twice after the initial incubation and incubated for a further 20 minutes in the presence of PE-conjugated streptavidine (Becton Dickinson). Cells were washed and analyzed on a FACScan fluorescent analyzer (Becton Dickinson).
lrnmunohisrochemisrr. Blocks of fresh splenic tissue were frozen in liquid nitrogen and stored at -70°C. Cryostat sections of 8-to IO-mm thickness were fixed in acetone for 10 minutes and airdried for at least 30 minutes. After washing in 0.01 molL PBS (pH 7.4) the sections were incubated with the antihuman CD45 MoAb (clone CLB-T200), which had been conjugated to horseradish peroxidase (HRP) using periodate. After washing, the peroxidase activity was shown with 3,3' diaminobenzidine-tetrahydrochloride (DAB, Sigma) in O S mg/mL TRIS HCI buffer (pH 7.6) containing 0.01% H202. The sections were stained for 10 minutes at room temperature. Acid phosphatase in the cryostat sections was determined as described by Eikelenboom.'3
RESULTS
To determine the effect of liposome-mediated depletion of murine macrophages on the ability of human cells to survive and circulate in vivo in SCID mice, a titration experiment was performed as described in Table 1 . After liposome treatment, human PB lymphocytes (PBLs) were introduced by intravenous injection and SCID mice were killed 24 or 72 hours later and analyzed for human cell content in PB, spleen, and BM. Representative SCID mice that received human PBLs are shown in Fig 1. Human cells were detectable at low levels in PB, spleen, and BM of nonliposometreated SCID mice 24 hours after intravenous injection when assayed by FACS for cells expressing human class I HLA (W632) and CD45 (Fig I , control 24 hours), but were completely devoid of detectable cells in these tissues within 72 hours postinjection (Fig 1, control 72 hours) . In contrast, human cells were detectable at high levels under all titration conditions at both 24 and 72 hours in these tissues, as shown in Fig 1 (treatment 2) . These results are summarized in Fig  2 and show that a great proportion of human cells reside in the spleen of liposome-treated animals with levels as high as 12.3% 24 hours postinjection and 6.7% 72 hours postinjection (Fig 2A, Splenic cryostat sections stained with acid-phosphatase to detect phagocytic macrophages show complete elimination of red-pulp and marginal-zone phagocytic macrophages with maintenance of some white-pulp macrophages in liposometreated animals when compared with controls (Fig 2, macrophages) . Cells staining positive for CD45 are not detectable in cryostat sections of control animals (Fig 2. CD45) . However, in liposome-treated animals, accumulation of human cells is found restricted to the white pulp and marginal zones. The extent of elimination of acid phosphatase-positive cells in the red-pulp region correlates with accumulation of human cells in the white-pulp region. This is particularly obvious in treatment 2 mice where red-pulp macrophages are completely eliminated, and the concentration of white pulp localized CD45-positive cells is the highest. The proportion of human cells in the PB and the spleen is dependent on the treatment provided. The higher dose treatment ( Table   1, treatments 1 and 2) allows human cells to circulate in the PB for at least 72 hours (Fig 2, mice 1-3 , 1-4, 2-3, 2-41, However, the observed effect is most strilung in treatment 2, which is the optimum treatment of those tested for retention of human cells in PB, spleen, and BM. Mice that received a modified treatment 2 regimen were also analyzed 7 and 12 days post-PBL injection for circulation of human cells (Fig 3, A and B) . A representative analysis of lineage distribution in a single mouse analyzed 12 days after human PBL injection (Fig 3A) shows that human T cells (CD4+ and CD8+) and B cells (CD209 could be easily detected by flow cytometry. In contrast, human cells were completely undetectable in PB and spleens (N = 12, 3 experiments) of control mice given PBS injections. The total number of human cells found in the SCID mouse spleens positive for CD45 and either T-cell markers CD4 and CD8 or B-cell marker CD20 were calculated (Fig 3B) . Both T and B cells could be found in the spleen of 10/11 liposome-treated animals at day 7 (3 experiments) and 15 of 17 SCID mice at day 12 (3 experiments). Although CD33+ cells were found in the PB and spleen 24 hours postinjection, none were found in PB or spleen either 7 or 12 days postinjection (data not shown). Both CD4+ and CD20+ cells dominated the CD45+ population at both 7 and 12 days post- PBL injection (with as many as 3.8 X lo4 CD4 cells in day 12-treated animal spleens). Circulating human B and T cells could also be detected in the PB, but at lower frequency than those found in the spleen at both 7 and 12 days (data not shown).
Although SCID-hu ThyLiv mice have substantial numbers of human cells in the grafts, the number of circulating cells in the periphery remains low. One postulation is that macrophages are playing a role in trapping and eliminating peripheral human cells in the spleen and liver.
To test this hypothesis, SCID-hu ThyLiv mice were given either sequential injections of PBS or ClzMDP liposomes, then analyzed by immunohistochemistry of cryostat sections for acid-phosphatase-positive phagocytic macrophages and human CD4Y cells, or by flow cytometry using murine myeloid specific antibodies. Staining of cryostat sections show very clearly the effect of liposome-mediated depletion on the spleen. In control mice (Fig 4A) , there is a uniform distribution of acid phosphatase-positive cells throughout the white-and red-pulp area as well as the marginal zone, and these areas are devoid of detectable CD45' cells ( Fig  4B) . The liposome-treated mice show a near-complete Qepletion of acid phosphatase-positive cells in the red pulp and marginal zone (Fig 4C) and an accumulation of CD45' cells around the central arteriole of the white pulp (Fig 4D) . In contrast with the acid-phosphatase staining for phagocytic macrophages, flow cytometric evaluation of myeloid cell content with antibodies specific to CD1 l b (Mac-l) and myeloid specific antigen (Gr-l) show an increase in the proportion of myeloid cells in liposome-treated mice compared with PBS controls (Fig 4, E and F) . Although an overall increase in myeloid content in the spleen is observed, acid phosphatase-positive cells were completely eliminated in 16 of 21 SCID-hu Thy/Liv mouse spleens when given 1 to 4 sequential injections of CI2MDP-liposomes ( Table 2 ). The complete elimination of acid phosphatase-positive cells correlated with the detection of CD45' cells by immunohistochemistry in the spleen ( Fig 4A, Table 2 ). These data confirm previously published results indicating that the elimination of cells is restricted to a subset of macrophages in the spleen that are acid phosphatase-positive and phagocytic."."
Evaluation of the human cell content in the PB and spleen of CI2MDP-liposome-treated animals (N = 23) compared with PBS-injected controls (N = 15) was performed using flow cytometry (Fig 5, A and B ). An increase in the percentage of human cells circulating in the PB of C12MDP-liposome-treated SCID-hu Thy/Liv mice (mean, 2.9%) was observed compared with PBS controls (mean, 0.5%) ( P < .001
by the Mann-Whitney U-test). Similarly, an increase in the number of human cells in the spleen of CI2MDP-liposometreated mice was observed (mean, 69,000 in C12MDP-liposome recipients, 44,000 in PBS recipients) ( P = .014 by the Mann-Whitney U-test).
To assess fluctuations in human cell circulation in SCIDhu ThyLiv mice in response to phagocytic macrophage depletion, SCID mice transplanted 1 year previously with fetal liver and thymus were screened for PB human cell both CD45' and CD4+, CD8' . or CD20' . SClD mice were treated as described in Table 1 , treatment 2 except modified by injection with 2 x lo7 PBL and an additional liposome injection 4 days after PBL injection. Mice were then killed for analysis 7 and 12 days post-PBL injection. Red blood cell lysed splenocytes were stained with either CD45-TC plus CDCFITC and CD8-PE, or CD45 plus CDZO-FITC and CD33-PE, and analyzed for three-color fluorescence. or 100% C12MDP-1iposome stock. SClD mice implanted with ThyILiv grafts were given a treatment of 1, 2, or 4 intravenous injections (one every 5 to 7 days) of 100% CI,MDP-liposome stock. Before death, a sample of tail vein peripheral blood (PB) was taken for flow cytometry. One half of the spleen was homogenized and used for flow cytometry. One half of the spleen was frozen in liquid nitrogen for cryostat sections and immunocytochemistryas described in Fig 2. Macrophage (acid phosphatase-positive cells) and CD45' cell content were evaluated as described.
+, no depletion; +I-, severely depleted, but some macrophages detectable in red pulp; -, red pulp depleted ofmacrophages.
content at days 1 and 12. On day 16, either PBS or liposome containing C12MDP was injected into the tail vein of these mice. PB samples were taken on days 18, 21, 25, 32, 41,47 and analyzed by FACscan for human cell content by triple staining with human class I HLA (W6/32), human leukocyte marker CD45, and murine leukocyte marker Ly5.1. Values for human cell percentages in PB were calculated by the proportion of W6/32-CD45 double-positive cells, and confirmed Ly5.1-negative. The results are summarized in Fig  6. Theoretically, based on results observed for macrophage recovery in normal (C3D2)Fl mice after liposome treatment, an increase in human cells in the periphery would occur immediately after injection, followed by a return to baseline levels with the recovery of murine macrophages within 1 to 2 weeks. 27 We observed that PBS control mice (N = 3) showed small fluctuations in levels of human cells in the periphery after injection (Fig 6B) . However, five of eight mice injected with liposomes showed an increase in human cells in the periphery 4 to 7 days postinjection (days 18 and 21, Fig 6A) , which was maintained at least 18 days postinjection, and returned to base levels by 27 days postinjection. The most striking of these were two mice in which human cell content in the PB increased from 0.3% to 0.5% pretreatment to 2.8% to 3.2% posttreatment (mouse 2 and 3, Fig 6A) and returned to 0.3% to 0.5% within 27 days postinjection.
DISCUSSION
The results described above indicate macrophages in the mononuclear phagocytic system of the SCID mouse may PERIPHERAL BLOOD 
-

I -
O I I m 3 0 PBS k 0
Day of analysis
play an important role in clearance of human cells in SCIDhu mouse models, and elimination of these cells by dichloromethylene diphosphonate-containing liposomes results in the ability of human cells to circulate and to survive for longer periods of time in the periphery. Human cells were completely undetectable in PB, spleen, and BM of normal SCID mice when human PBLs were injected intravenously and mice were analyzed 72 hours later for cells positive for human class I and CD45 by FACS. In contrast, human cells were easily detected in mice pretreated with liposome-encapsulated C12MDP 12 days after injection of human PBLs. In addition, a single injection of liposome-encapsulated C1,MDP into SCID-hu Thy/Liv mice resulted in an increase of human cells circulating in mouse PB for at least 2 weeks postinjection, following previously reported data on kinetics of recovery of macrophages in normal mice after liposome but does not eliminate splenic white-pulp macrophages in normal mice or in SCID mice as described here, presumably because the microcirculation in the white-pulp region of the spleen does not allow immediate access to liposomes entering the spleen.35 The coexistence of murine macrophages with human cells in this region suggests that this population of macrophages is not directly responsible for killing human cells. Our experiments do not address the potential effect of ClzMDP liposomes on other murine populations that may be involved in human cell killing such as NK cells. In fact the observation of variability of human cell content within cohorts of mice with identical treatments indicates other physiologic factors or cell types may also be involved. Previous reports have shown that elimination of NK cells with antiasialo GM1 antiserum can increase the frequency of circulating cells in SCID-hu mice,36 and combined with irradiation can enhance growth of human lymphomas." Treatment of mice with C1,MDP-liposomes has been shown to be highly specific for phagocytic cells (monocytes/ macrophages) only:' and our data confirms that only a subset of macrophages is eliminated.
The ability to enhance and prolong circulation of human cells in the SCID mouse with prolonged C12MDP-liposome treatment increases the potential for study of human hematopoietic, immunologic, and disease processes in vivo. Prolonged circulation of human cells in the periphery may provide a means for in vivo study of human cell functions such as homing, engraftment, and tumor or allogeneic rejection of foreign tissues that were previously not feasible. Maintenance of circulating human BM or PBL for longer periods should improve the potential of these populations to home to various tissues, and decrease the cell dose required for engraftment, making it possible to study development of defined human hematopoietic cell subtypes such as purified stem cells. Finally, the ability of human cells to circulate more freely may enhance propagation of cells from tumors or proliferative disorders such as acute or chronic myeloid leukemia that have been shown to have the capacity to grow and circulate in SCID mice.'
